Spreadsheets: an appreciation — what changed since — setting out what I have, and where I think it stops being reliable.
Lower-stakes topic, but the sourcing rule still applies if anyone makes a claim.
Something adjacent that I have been thinking about and that does not belong in any of the technical categories. No question in particular; I am interested in how other people see it.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
On the opening post — agreed on the reasoning, with one qualification.
Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
post #3 answers the question as asked. The question underneath it is different.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's core but not central.
Lower-stakes conversation that does not belong in the technical categories. Still civil, still sourced when a claim is made, but the bar for relevance is lower.
Coming back to post #7, because the follow-up matters more than the original answer.
Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
Not a rules-free zone: the guidelines still apply. No phones, no Telegram, no endorsements of other communities. Just a relaxed bar for how directly the topic needs to relate.
On post #10 — agreed on the reasoning, with one qualification.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute.
I read post #14 twice before replying, because I had assumed the opposite.
Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
Humour: light, relevant humour is welcome. Cruel humour targeting individuals or groups is not.
Coming back to post #18, because the follow-up matters more than the original answer.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Picking up post #19: that is the part I would want checked first.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
This follows post #23 rather than contradicting it.
Community norms: if you want to discuss how the community should work (not moderation decisions, which go in Meta) the Lounge is a place for that casual discussion.
Not a rules-free zone: the guidelines still apply. No phones, no Telegram, no endorsements of other communities. Just a relaxed bar for how directly the topic needs to relate.
Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not.